<DOC>
	<DOCNO>NCT00272077</DOCNO>
	<brief_summary>Primary objective : To evaluate explorative manner fast blood glucose ( FBG ) coefficient variability ( CV ) calculate SMBG value ( SMBG : Self-Monitoring Blood Glucose ) . Secondary objective : The secondary objective assessment : change glycaemic control ( HbA1C ) , frequency hypoglycaemia , change weight , final insulin dose , change lipid parameter , change urinary albumin-to-creatinine ratio , profile patient best fit algorithms dependent variable change HbA1C independent variable age , gender , race , tobacco use , diabetes complication , initial HbA1C , initial weight , duration diabetes mellitus , general education diabetes education .</brief_summary>
	<brief_title>Insulin Glargine Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diagnosis type 2 diabetes mellitus least 5 year ; Treatment oral antidiabetic drug fix combination ( Combo , i.e . glibenclamide 2.5 mg + metformin 400 mg , 2 3 tablet , stable dose last 3 month ) ; HbA1c &gt; = 8 % &lt; = 11 % ; Body mass index ( BMI ) &gt; 27 &lt; 35 kg/m2 ; Willingness demonstrate ability inject insulin ; Demonstrated ability willingness perform selfmonitoring blood glucose ( SMBG ) ; Exclusion criterion : Patients diagnose type 1 insulin dependent diabetes ; Patients latent autoimmune diabetes adult ( LADA ) , define fast Cpeptide level &lt; 1 ng/ml ; Cardiac status NYHA IIIIV ; Impaired renal function show ( limited ) serum creatinine &gt; = 1.5 mg/dl male &gt; = 1.4 mg/dl female ; Planned pregnancy , pregnant lactating female ; Failure use adequate contraception ( woman current reproductive potential ) ; Any current malignancy , previous breast cancer , malignant melanoma within past 5 year ; Diagnosis dementia Hypersensitivity insulin component metformin ; Current previous insulin therapy hospitalisation ; Inability unwillingness continue metformin study dosage throughout study ; Treatment intermittent dos systemic steroid large dos inhale steroid past one year ( fixed dos past 6 month acceptable providing plan change dosage regime ) ; Stroke , Myocardial Infarction ( MI ) , Coronary Artery Bypass Graft ( CABG ) , Percutaneous Transluminal Coronary Angioplasty ( PTCA ) , Angina Pectoris within last 12 month ; History drug alcohol abuse ; Receipt experimental drug use experimental device within 30 day prior study entry ;</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>